Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome

Therapeutic Drug Monitoring of Posaconazole in Hematology Patients: Experience with a New High-Performance Liquid Chromatography-Based Method

(2010) W. C. Neubauer et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Posaconazole Serum Concentrations among Cardiothoracic Transplant Recipients: Factors Impacting Trough Levels and Correlation with Clinical Response to Therapy

(2010) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Exposure–Response of Posaconazole Used for Prophylaxis Against Invasive Fungal Infections: Evaluating the Need to Adjust Doses Based on Drug Concentrations in Plasma

(2010) S H Jang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Posaconazole: clinical pharmacokinetics and drug interactions

(2010) Hans-Peter Lipp   MYCOSES

Correlation of In Vitro Activity, Serum Levels, and In Vivo Efficacy of Posaconazole against Rhizopus microsporus in a Murine Disseminated Infection

(2009) M. M. Rodriguez et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of Varying Amounts of a Liquid Nutritional Supplement on the Pharmacokinetics of Posaconazole in Healthy Volunteers

(2009) G. Krishna et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Factors Influencing Pharmacokinetics of Prophylactic Posaconazole in Patients Undergoing Allogeneic Stem Cell Transplantation

(2009) V. Kohl et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Posaconazole Therapeutic Drug Monitoring: a Reference Laboratory Experience

(2009) G. R. Thompson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Therapeutic Drug Monitoring of Posaconazole: a Monocentric Study with 54 Adults

(2009) D. Lebeaux et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Omeprazole Significantly Reduces Posaconazole Serum Trough Level

(2009) Jan‐Willem C. Alffenaar et al.   CLINICAL INFECTIOUS DISEASES

Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome

(2009) M.A. AbuTarif et al.   CURRENT MEDICAL RESEARCH AND OPINION

The changing face of epidemiology of invasive fungal disease in Europe

(2009) Cornelia Lass-Flörl   MYCOSES

Pharmacokinetics and Absorption of Posaconazole Oral Suspension under Various Gastric Conditions in Healthy Volunteers

(2008) G. Krishna et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America

(2008) Thomas J. Walsh et al.   CLINICAL INFECTIOUS DISEASES

Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology

(2008) O. A. Cornely et al.   HAEMATOLOGICA

Update on the epidemiology and diagnosis of invasive fungal infection

(2008) Manuel Cuenca-Estrella et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Pharmacokinetics of Oral Posaconazole in Neutropenic Patients Receiving Chemotherapy for Acute Myelogenous Leukemia or Myelodysplastic Syndrome

(2008) Gopal Krishna et al.   PHARMACOTHERAPY

Breakthrough invasive fungal infection in an immunocompromised host while on posaconazole prophylaxis: an omission in patient counseling and follow-up

(2008) Joseph J Kishel et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE